Citius Oncology, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Citius Oncology, Inc. (CTOR) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $3.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-14
- Citius Oncology, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $3.56M, a 67.55% increase year-over-year.
- Citius Oncology, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $3.53M, a 68.86% increase year-over-year.
- Citius Oncology, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-12-31 was $3.96M, a 118.75% increase year-over-year.
- Citius Oncology, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $2.13M, a 8.60% increase year-over-year.
- Citius Oncology, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $8.32M, a 10.96% increase from fiscal 2024.
- Citius Oncology, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $7.50M, a 281.52% increase from fiscal 2023.
- Citius Oncology, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $1.97M.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.56M 10-Q · filed 2026-08-14 | $7.09M derived: sum of 2 quarters · filed 2026-08-14 | $11.04M derived: sum of 3 quarters · filed 2026-08-14 | |
| 2026-03-31 | $3.53M 10-Q · filed 2026-08-14 | $7.48M derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2025-12-31 | $3.96M 10-Q · filed 2026-08-14 | |||
| 2025-09-30 | $8.32M 10-K · filed 2025-12-23 | |||
| 2025-06-30 | $2.13M 10-Q · filed 2026-08-14 | $4.21M derived: sum of 2 quarters · filed 2026-08-14 | $6.02M derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-03-31 | $2.09M 10-Q · filed 2026-08-14 | $3.90M derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2024-12-31 | $1.81M 10-Q · filed 2026-08-14 | |||
| 2024-09-30 | $7.50M 10-K · filed 2025-12-23 | |||
| 2024-06-30 | $1.96M 10-Q · filed 2025-08-12 | $3.91M derived: sum of 2 quarters · filed 2025-08-12 | $5.83M derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | $1.96M 10-Q · filed 2025-08-12 | $3.87M derived: sum of 2 quarters · filed 2025-08-12 | ||
| 2023-12-31 | $1.92M 10-Q · filed 2025-08-12 | |||
| 2023-09-30 | $1.97M 10-K · filed 2024-12-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |